MARATTO

review · British Journal of Clinical Pharmacology

Cross‐disciplinary mathematical modelling to benefit healthcare – could clinical pharmacology play an enabling role?

20241 citationOpen accessStellenbosch University

Abstract

Clinical pharmacology is often the nexus in any cross-disciplinary team that is seeking solutions for human healthcare issues. The use and application of real-world data and artificial intelligence to better understand our ecosystem has influenced our view at the world and how we do things. This has resulted in remarkable advancements in the healthcare space and development of personalized medicines with great attributes from the application of models and simulations, contributing to a more efficient healthcare development process. A cross-disciplinary symposium was held in December 2023, whereby experts from different scientific disciplines engaged in a high-level discussion on the opportunities and challenges of mathematical models in different fields, possible future developments and decision making. A strong interlink amongst the disciplines represented was apparent, with clinical pharmacology identified as the one which integrates various scientific disciplines. Deliberate and strategic cross-disciplinary dialogues are required to break out of the silos and implement integration for efficiency and cost-effectiveness of novel interventions.

Research topics

  • Health Systems, Economic Evaluations, Quality of Life
  • Health and Medical Research Impacts
  • Statistical Methods in Clinical Trials

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1111/bcp.16192

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.